374 related articles for article (PubMed ID: 34544752)
1. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.
Li Q; Jiang B; Guo J; Shao H; Del Priore IS; Chang Q; Kudo R; Li Z; Razavi P; Liu B; Boghossian AS; Rees MG; Ronan MM; Roth JA; Donovan KA; Palafox M; Reis-Filho JS; de Stanchina E; Fischer ES; Rosen N; Serra V; Koff A; Chodera JD; Gray NS; Chandarlapaty S
Cancer Discov; 2022 Feb; 12(2):356-371. PubMed ID: 34544752
[TBL] [Abstract][Full Text] [Related]
2. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
[TBL] [Abstract][Full Text] [Related]
3. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
4. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
5. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R
Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Biological Evaluation of Novel
Song X; Gan Q; Zhang X; Zhang J
Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
[TBL] [Abstract][Full Text] [Related]
9. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
10. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
11. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.
Wu X; Yang X; Xiong Y; Li R; Ito T; Ahmed TA; Karoulia Z; Adamopoulos C; Wang H; Wang L; Xie L; Liu J; Ueberheide B; Aaronson SA; Chen X; Buchanan SG; Sellers WR; Jin J; Poulikakos PI
Nat Cancer; 2021 Apr; 2(4):429-443. PubMed ID: 34568836
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors.
Jeffrey PD; Tong L; Pavletich NP
Genes Dev; 2000 Dec; 14(24):3115-25. PubMed ID: 11124804
[TBL] [Abstract][Full Text] [Related]
13. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Wander SA; Cohen O; Gong X; Johnson GN; Buendia-Buendia JE; Lloyd MR; Kim D; Luo F; Mao P; Helvie K; Kowalski KJ; Nayar U; Waks AG; Parsons SH; Martinez R; Litchfield LM; Ye XS; Yu C; Jansen VM; Stille JR; Smith PS; Oakley GJ; Chu QS; Batist G; Hughes ME; Kremer JD; Garraway LA; Winer EP; Tolaney SM; Lin NU; Buchanan SG; Wagle N
Cancer Discov; 2020 Aug; 10(8):1174-1193. PubMed ID: 32404308
[TBL] [Abstract][Full Text] [Related]
14. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
[TBL] [Abstract][Full Text] [Related]
15. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
16. HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
Zhou Y; Jin X; Ma J; Ding D; Huang Z; Sheng H; Yan Y; Pan Y; Wei T; Wang L; Wu H; Huang H
Cancer Res; 2021 Mar; 81(6):1486-1499. PubMed ID: 33419772
[TBL] [Abstract][Full Text] [Related]
17. Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.
Jiang B; Wang ES; Donovan KA; Liang Y; Fischer ES; Zhang T; Gray NS
Angew Chem Int Ed Engl; 2019 May; 58(19):6321-6326. PubMed ID: 30802347
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory.
Lelliott EJ; Kong IY; Zethoven M; Ramsbottom KM; Martelotto LG; Meyran D; Zhu JJ; Costacurta M; Kirby L; Sandow JJ; Lim L; Dominguez PM; Todorovski I; Haynes NM; Beavis PA; Neeson PJ; Hawkins ED; McArthur GA; Parish IA; Johnstone RW; Oliaro J; Sheppard KE; Kearney CJ; Vervoort SJ
Cancer Discov; 2021 Oct; 11(10):2582-2601. PubMed ID: 33990344
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold.
Shan H; Ma X; Yan G; Luo M; Zhong X; Lan S; Yang J; Liu Y; Pu C; Tong Y; Li R
Eur J Med Chem; 2021 Jul; 219():113432. PubMed ID: 33857728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
